1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Market Study on Duchenne Muscular Dystrophy: Europe to Lead the Global Market in Terms of Revenue during 2017 - 2026

Global Market Study on Duchenne Muscular Dystrophy: Europe to Lead the Global Market in Terms of Revenue during 2017 - 2026

  • January 2018
  • 170 pages
  • ID: 5351019
  • Format: PDF
  • By Persistence Market Research

Summary

Table of Contents

Global Duchenne Muscular Dystrophy Market- Overview
Duchenne Muscular Dystrophy (DMD) is one of the most common types of genetic disorder that results in muscle degeneration. Currently there is no curative treatment for DMD, however, various organizations are investing in the research and development, in order to find an effective treatment for DMD. Gene therapy as the treatment for DMD is in an early stage of development.

The U.S. Food and Drugs Administration (FDA) in 2015 published guidelines for developing a drug for duchenne muscular dystrophy.
Hence, these guidelines are expected to contribute towards new drug development to treat duchenne muscular dystrophy. Most of the DMD disorders can be detected during pregnancy, technically advanced devices are being developed for muscle biopsy test and prenatal tests for diagnosis. Also, small drugs for downstream defects are in clinical trials.

However, lack of standardization to measure efficacy across all the stages of DMD and the high cost of novel drugs are hampering the growth of the global duchenne muscular dystrophy market.

Global Duchenne Muscular Dystrophy Market- Research Methodology
The report on the global duchenne muscular dystrophy market gives important perceptions on the overall market. The report offers critical insights focusing on the financial and technical details of the market.

The market research report aims to provide key trends, various driving factors, opportunities in the market and factors hampering the market growth. The worldwide duchenne muscular dystrophy market analysis report includes market overview, growth, demand and research on the performance of the market in major regions across the globe.

Both primary and secondary research was done by the expert analysts to provide a forecast on the market including revenue, CAGR, and year-on-year growth along with the information that will impact the market in the long run.

The primary research was done by conducting interviews with market experts and details provided by them were crosschecked with valid sources. While, financial reports, annual reports of the key companies and investor presentation formed the part of the secondary research.

The report also comprises SWOT analysis, Porter’s Five Force analysis. The report also provides regional overview along with market segmentation along with the details on the most attractive segments in the global duchenne muscular dystrophy market.

The report also provides competitive landscape including profiles of the key players operating in the global duchenne muscular dystrophy market. The report offers details on the key players including financial overview, company overview, product portfolio, key developments and long-term and short-term strategies by businesses.

The global duchenne muscular dystrophy market is segmented on the basis of product type, distribution channel, therapy, and region. On the basis of product type, the market is segmented into NSAIDs, Corticosteroids, and other products. By distribution channel, the market segmentation includes Hospital Pharmacies, Retail Pharmacies, and online pharmacies.

Based on the therapy, the market is segmented into Mutation Suppression, Exon Skipping Approach, and other therapies. The global duchenne muscular dystrophy market segmented on the basis of region includes Europe, Japan, Latin America, Asia Pacific Excluding Japan (APEJ), North America, and the Middle East and Africa (MEA).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off

($4900)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Endometriosis - Pipeline Review, H2 2019

Endometriosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Endometriosis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2019, provides an overview of the Endometriosis (Women’s ...

Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019

Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019SummaryRetinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close ...

Dementia - Pipeline Review, H2 2019

Dementia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Dementia - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2019, provides an overview of the Dementia (Central Nervous System) ...

Stroke - Pipeline Review, H2 2019 $ 2500 November 2019


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on